Bendamustine Hydrochloride
"Bendamustine Hydrochloride" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A nitrogen mustard compound that functions as an ALKYLATING ANTINEOPLASTIC AGENT and is used in the treatment of CHRONIC LYMPHOCYTIC LEUKEMIA and NON-HODGKIN'S LYMPHOMA.
| Descriptor ID |
D000069461
|
| MeSH Number(s) |
D02.241.081.114.625 D02.455.526.728.650.103 D03.633.100.103.123
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Bendamustine Hydrochloride".
Below are MeSH descriptors whose meaning is more specific than "Bendamustine Hydrochloride".
This graph shows the total number of publications written about "Bendamustine Hydrochloride" by people in this website by year, and whether "Bendamustine Hydrochloride" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2012 | 0 | 1 | 1 |
| 2015 | 0 | 2 | 2 |
| 2017 | 1 | 3 | 4 |
| 2018 | 5 | 3 | 8 |
| 2019 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Bendamustine Hydrochloride" by people in Profiles.
-
Case Report: Stepwise Anti-Inflammatory and Anti-SARS-CoV-2 Effects Following Convalescent Plasma Therapy With Full Clinical Recovery. Front Immunol. 2021; 12:613502.
-
Orphan Drug Designation and Exclusivity for "Same Drugs". J Law Med Ethics. 2019 06; 47(2):347-349.
-
CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia. Leukemia. 2019 05; 33(5):1161-1172.
-
Establishment of a comprehensive chronic lymphocytic leukemia clinic at a tertiary referral center in India. Blood Adv. 2018 11 30; 2(Suppl 1):33-34.
-
Bendamustine and Rituximab Treatment, Chronic Lymphocytic Leukemia, Direct Antiglobulin Test, and False Negatives Turk J Haematol. 2019 02 07; 36(1):53-54.
-
Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018 09; 19(9):1215-1228.
-
Treatment of IgM-associated immunoglobulin light-chain amyloidosis with rituximab-bendamustine. Blood. 2018 08 16; 132(7):761-764.
-
Bendamustine plus rituximab in chronic lymphocytic leukemia: is there life in the old dog yet? Haematologica. 2018 04; 103(4):563-564.
-
CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia. Future Oncol. 2018 Mar; 14(6):499-513.
-
Rituximab-Bendamustine (R-Benda) in MALT lymphoma complicating primary Sjögren syndrome (pSS). Br J Haematol. 2019 02; 184(3):472-475.